179 related articles for article (PubMed ID: 36010887)
1. Critical Requirement of SOS1 for Development of BCR/ABL-Driven Chronic Myelogenous Leukemia.
Gómez C; Garcia-Navas R; Baltanás FC; Fuentes-Mateos R; Fernández-Medarde A; Calzada N; Santos E
Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36010887
[TBL] [Abstract][Full Text] [Related]
2. Phosphorylation of SOS1 on tyrosine 1196 promotes its RAC GEF activity and contributes to BCR-ABL leukemogenesis.
Gerboth S; Frittoli E; Palamidessi A; Baltanas FC; Salek M; Rappsilber J; Giuliani C; Troglio F; Rolland Y; Pruneri G; Kreutmair S; Pallavicini I; Zobel M; Cinquanta M; Minucci S; Gomez C; Santos E; Illert AL; Scita G
Leukemia; 2018 Mar; 32(3):820-827. PubMed ID: 28819285
[TBL] [Abstract][Full Text] [Related]
3. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow.
Pear WS; Miller JP; Xu L; Pui JC; Soffer B; Quackenbush RC; Pendergast AM; Bronson R; Aster JC; Scott ML; Baltimore D
Blood; 1998 Nov; 92(10):3780-92. PubMed ID: 9808572
[TBL] [Abstract][Full Text] [Related]
4. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.
Zhang X; Ren R
Blood; 1998 Nov; 92(10):3829-40. PubMed ID: 9808576
[TBL] [Abstract][Full Text] [Related]
5. Rac GTPases as key regulators of p210-BCR-ABL-dependent leukemogenesis.
Thomas EK; Cancelas JA; Zheng Y; Williams DA
Leukemia; 2008 May; 22(5):898-904. PubMed ID: 18354486
[TBL] [Abstract][Full Text] [Related]
6. Acquired loss of p53 induces blastic transformation in p210(bcr/abl)-expressing hematopoietic cells: a transgenic study for blast crisis of human CML.
Honda H; Ushijima T; Wakazono K; Oda H; Tanaka Y; Aizawa Si; Ishikawa T; Yazaki Y; Hirai H
Blood; 2000 Feb; 95(4):1144-50. PubMed ID: 10666183
[TBL] [Abstract][Full Text] [Related]
7. The biology of chronic myelogenous leukemia:mouse models and cell adhesion.
Wertheim JA; Miller JP; Xu L; He Y; Pear WS
Oncogene; 2002 Dec; 21(56):8612-28. PubMed ID: 12476308
[TBL] [Abstract][Full Text] [Related]
8. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia].
Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ
Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985
[TBL] [Abstract][Full Text] [Related]
9. Requirement of c-Myb for p210(BCR/ABL)-dependent transformation of hematopoietic progenitors and leukemogenesis.
Lidonnici MR; Corradini F; Waldron T; Bender TP; Calabretta B
Blood; 2008 May; 111(9):4771-9. PubMed ID: 18227349
[TBL] [Abstract][Full Text] [Related]
10. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.
Li S; Ilaria RL; Million RP; Daley GQ; Van Etten RA
J Exp Med; 1999 May; 189(9):1399-412. PubMed ID: 10224280
[TBL] [Abstract][Full Text] [Related]
11. Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder.
Hao SX; Ren R
Mol Cell Biol; 2000 Feb; 20(4):1149-61. PubMed ID: 10648600
[TBL] [Abstract][Full Text] [Related]
12. The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase.
Roumiantsev S; de Aos IE; Varticovski L; Ilaria RL; Van Etten RA
Blood; 2001 Jan; 97(1):4-13. PubMed ID: 11133737
[TBL] [Abstract][Full Text] [Related]
13. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
Gross AW; Ren R
Oncogene; 2000 Dec; 19(54):6286-96. PubMed ID: 11175343
[TBL] [Abstract][Full Text] [Related]
14. Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL.
Li S; Gillessen S; Tomasson MH; Dranoff G; Gilliland DG; Van Etten RA
Blood; 2001 Mar; 97(5):1442-50. PubMed ID: 11222392
[TBL] [Abstract][Full Text] [Related]
15. Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571.
Wolff NC; Ilaria RL
Blood; 2001 Nov; 98(9):2808-16. PubMed ID: 11675355
[TBL] [Abstract][Full Text] [Related]
16. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis.
Koschmieder S; Göttgens B; Zhang P; Iwasaki-Arai J; Akashi K; Kutok JL; Dayaram T; Geary K; Green AR; Tenen DG; Huettner CS
Blood; 2005 Jan; 105(1):324-34. PubMed ID: 15331442
[TBL] [Abstract][Full Text] [Related]
17. Functional Specificity of the Members of the Sos Family of Ras-GEF Activators: Novel Role of Sos2 in Control of Epidermal Stem Cell Homeostasis.
Baltanás FC; Mucientes-Valdivieso C; Lorenzo-Martín LF; Fernández-Parejo N; García-Navas R; Segrelles C; Calzada N; Fuentes-Mateos R; Paramio JM; Bustelo XR; Santos E
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33946974
[TBL] [Abstract][Full Text] [Related]
18. [Generation and identification of P210(T315I-BCR/ABL) transgenic mice].
Zhu Y; Wang Y; Meng F
Zhonghua Xue Ye Xue Za Zhi; 2015 Mar; 36(3):221-4. PubMed ID: 25854466
[TBL] [Abstract][Full Text] [Related]
19. The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl.
He Y; Wertheim JA; Xu L; Miller JP; Karnell FG; Choi JK; Ren R; Pear WS
Blood; 2002 Apr; 99(8):2957-68. PubMed ID: 11929787
[TBL] [Abstract][Full Text] [Related]
20. Targeting SOS1 overcomes imatinib resistance with BCR-ABL independence through uptake transporter SLC22A4 in CML.
Liu Y; Li C; Su R; Yin Z; Huang G; Yang J; Li Z; Zhang K; Fei J
Mol Ther Oncolytics; 2021 Dec; 23():560-570. PubMed ID: 34938856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]